Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hTERT DNA vaccine - Invectys

Next Previous
X
Search
Drug Profile

hTERT DNA vaccine - Invectys

Alternative Names: hTERT DNA immunotherapy - Invectys; Human telomerase reverse transcriptase DNA vaccine - Invectys; INVAC-1

Latest Information Update: 28 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Invectys
  • Developer Invectys; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • No development reported Solid tumours

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in France (Intradermal, Injection)
  • 26 Oct 2021 Personalis has patent protection for NeXT liquid biopsy, genomic sequencing and analysis solutions platforms and patents pending for cancer detection and data interpretation platforms in the US and worldwide as of October 2021
  • 10 Apr 2021 Final adverse events and immunogenicity data from a phase I trial in Solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top